Aileron Therapeutics, Inc. (NASDAQ:ALRN)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $14.92 and last traded at $14.92, with a volume of 37,122 shares trading hands. The stock had previously closed at $14.42.

Several research firms have recently issued reports on ALRN. Bank of America Corporation began coverage on Aileron Therapeutics in a research note on Monday, July 24th. They set a “buy” rating and a $19.00 target price on the stock. William Blair began coverage on Aileron Therapeutics in a research note on Monday, July 24th. They set an “outperform” rating on the stock. Jefferies Group LLC began coverage on Aileron Therapeutics in a research note on Monday, July 24th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Canaccord Genuity began coverage on Aileron Therapeutics in a research note on Monday, July 24th. They set a “buy” rating and a $19.00 target price on the stock.

The stock’s market cap is $214.25 million. The firm’s 50 day moving average is $12.51 and its 200-day moving average is $12.62.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. purchased a new position in Aileron Therapeutics during the 2nd quarter worth $111,000. Tudor Investment Corp ET AL purchased a new position in Aileron Therapeutics during the 2nd quarter worth $112,000. Citadel Advisors LLC purchased a new position in Aileron Therapeutics during the 2nd quarter worth $141,000. Neuberger Berman Group LLC purchased a new position in Aileron Therapeutics during the 2nd quarter worth $279,000. Finally, Laurion Capital Management LP purchased a new position in Aileron Therapeutics during the 2nd quarter worth $335,000. Institutional investors own 12.30% of the company’s stock.

WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/aileron-therapeutics-inc-alrn-hits-new-52-week-high-at-14-92/1611401.html.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Receive News & Ratings for Aileron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.